Identifying potential and druggable targets for developing new drugs is the first major step for curing a disease, which includes the understanding of the cellular, molecular, biochemical complexities associated with a specific disease. The classical hypothesis of ‘one gene, one drug, one disease’ in the drug discovery paradigm may have contributed to the low success rate in drug development. Using AI and related technologies in the target identification process allows scientists and pharmaceutical companies to really explore all the available evidence to better understand a disease and its underlying biology. Our team has focused on target identification, with growing amounts of data supporting early decision making.